BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17319092)

  • 21. Concern about one drug or entire class of drugs.
    Curković B
    Reumatizam; 2005; 52(1):5-6. PubMed ID: 16689104
    [No Abstract]   [Full Text] [Related]  

  • 22. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
    Andersohn F; Schade R; Suissa S; Garbe E
    Stroke; 2006 Jul; 37(7):1725-30. PubMed ID: 16728684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The COX-2 inhibitors--an update.
    Furberg CD
    Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
    [No Abstract]   [Full Text] [Related]  

  • 24. Raising the safety bar--the FDA's coxib meeting.
    Okie S
    N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
    [No Abstract]   [Full Text] [Related]  

  • 25. [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
    Guo ZR
    Yao Xue Xue Bao; 2005 Nov; 40(11):967-9. PubMed ID: 16499077
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
    Huang WF; Hsiao FY; Tsai YW; Wen YW; Shih YT
    Drug Saf; 2006; 29(3):261-72. PubMed ID: 16524325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COX-2 inhibitors--lessons in drug safety.
    Psaty BM; Furberg CD
    N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
    [No Abstract]   [Full Text] [Related]  

  • 28. COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs.
    Cimbollek S; Quiralte J; Avila R
    N Engl J Med; 2009 Nov; 361(22):2197-8. PubMed ID: 19940308
    [No Abstract]   [Full Text] [Related]  

  • 29. Ocular adverse effects associated with cyclooxygenase-2 inhibitors.
    Fraunfelder FW; Solomon J; Mehelas TJ
    Arch Ophthalmol; 2006 Feb; 124(2):277-9. PubMed ID: 16476901
    [No Abstract]   [Full Text] [Related]  

  • 30. Cardiovascular risk associated with celecoxib.
    Brophy JM
    N Engl J Med; 2005 Jun; 352(25):2648-50; author reply 2648-50. PubMed ID: 15972876
    [No Abstract]   [Full Text] [Related]  

  • 31. Coxibs and cardiovascular disease.
    Fitzgerald GA
    N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192
    [No Abstract]   [Full Text] [Related]  

  • 32. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
    Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COX-2 inhibitors and cardiovascular risk.
    Salzberg DJ; Weir MR
    Subcell Biochem; 2007; 42():159-74. PubMed ID: 17612050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database.
    Durrieu G; Olivier P; Montastruc JL;
    Eur J Clin Pharmacol; 2005 Sep; 61(8):611-4. PubMed ID: 16133552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cyclooxygenase inhibitors: a never ending story?].
    Macrì R; Manfredi C
    G Ital Cardiol (Rome); 2006 Jul; 7(7):505-7. PubMed ID: 16977790
    [No Abstract]   [Full Text] [Related]  

  • 38. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
    McGettigan P; Henry D
    JAMA; 2006 Oct; 296(13):1633-44. PubMed ID: 16968831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
    Hsiang KW; Chen TS; Lin HY; Luo JC; Lu CL; Lin HC; Lee KC; Chang FY; Lee SD
    Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
    Mukherjee D
    Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.